Virax Biolabs VRAX +42.53% ▲ stock rocketed higher on Wednesday after the biotechnology company’s CEO, James Foster, provided investors with an update on its operations. Highlights from this message included full recruitment into its first UK clinical study for VRX-002, initiation of a second UK-based trial, a clinical collaboration with Emory University, ongoing development of its ImmuneSelect research-use-only portfolio of immune-profiling reagents, and a debt-free balance sheet with enough cash to focus on near-term commercial and scientific priorities.
https://www.tipranks.com/news/why-is-virax-biolabs-vrax-stock-rocketing-higher-today
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.